PMA device
Hymovis
Fidia Farmaceutici · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Aug 28, 2015, newest Aug 28, 2015Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
7
Naming "Hymovis"
MAUDE reports
26
Brand "Hymovis", since 2015
PubMed studies
0
Mentioning "Hymovis"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- HYMOVISPMA
P150010 · Decided Aug 28, 2015 · 184 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Hymovis", any status and sponsor, newest update first.
- Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee OsteoarthritisPivotal-lookingCompleted
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT06528600 · 350 participants · Start Sep 16, 2020 · Primary completion Mar 15, 2024
Device: Hymovis ONE; Monovisc · For: Osteoarthritis, Knee
Sites: Brescia, Italy; Esine, Italy; Caserta, Italy · 19 sites in all
Concordia Hospital RomeAcademic, hospital or other
NCT06043544 · 80 participants · Start May 2, 2021 · Primary completion Nov 10, 2021
Device: Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe · For: Glenohumeral Osteoarthritis
Sites: Rome, Italy
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT04661111 · 31 participants · Start Jun 13, 2016 · Primary completion Sep 28, 2017
Device: Hymovis® ONE (32 mg/4 ml) · For: Knee Osteoarthritis
Sites: Roma, Italy
Fidia Pharma USA Inc.Not on our public-company list
NCT03281837 · 148 participants · Start Oct 1, 2017 · Primary completion Jul 9, 2020
Device: HYMOVIS plus Physical Exercise Program (PEP) · For: Osteoarthritis, Knee; Knee Osteoarthritis; Patellofemoral Osteoarthritis
Sites: Tucson, Arizona; Encinitas, California; Los Angeles, California · 10 sites in all
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT04293861 · 50 participants · Start Apr 1, 2015 · Primary completion Jun 6, 2017
Device: HYMOVIS · For: Knee Osteoarthritis
Sites: Yvoir, Belgium; Brussels, Belgium; Liège, Belgium · 8 sites in all
- Safety and Effectiveness Study of a Non-Crosslinked HA Alkylamide HYADD(TM) 4 Hydrogel for Osteoarthritis of the KneePivotal-lookingStatus unknown
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT02187549 · 332 participants (planned) · Start Jun 2014 · Primary completion Feb 2016
Device: HYMOVIS; Placebo · For: Knee Osteoarthritis
Sites: Birmingham, Alabama; Brimingham, Alabama; Phoenix, Arizona · 21 sites in all
- Hymovis™ Versus Placebo in Knee OsteoarthritisPivotal-lookingCompleted
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT01372475 · 800 participants · Start Mar 2011 · Primary completion Nov 2012
Device: Hymovis Intra-articular Injection · For: Knee Osteoarthritis
Sites: Birmingham, Alabama; Tucson, Arizona; Encinitas, California · 33 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hymovis", and for the whole product code for context.
This brand
26 reports: 0 malfunction, 26 injury, 0 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- HYMOVISInjury
9610200-2026-00002 · Received Jul 7, 2026 · Event dated Jun 11, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Appropriate Device Problem Term/Code Not Available
Patient problem as coded: Arthralgia; Swelling/ Edema
- HYMOVISInjury
3009107511-2025-00001 · Received Jun 27, 2025
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Arthritis; Fever; Arthralgia; Ambulation or Postural Difficulties; Administration Site Reaction; Administration Site Swelling
- HYMOVISInjury
3009107511-2025-00002 · Received Jun 27, 2025 · Event dated Apr 14, 2025
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Chest Pain; Dyspnea; Dizziness; Arthralgia; Joint effusion
- HYMOVISInjury
9610200-2025-00004 · Received Jun 26, 2025
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Arthritis; Fever; Arthralgia; Ambulation or Postural Difficulties; Administration Site Reaction; Administration Site Swelling
- HYMOVISInjury
9610200-2025-00005 · Received Jun 26, 2025 · Event dated Apr 14, 2025
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Chest Pain; Dyspnea; Dizziness; Arthralgia; Joint effusion
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Hymovis"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.